Advancells
Noida, India· Est.
India’s leading GMP‑compliant stem‑cell and exosome therapy provider for personalized regenerative medicine.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
India’s leading GMP‑compliant stem‑cell and exosome therapy provider for personalized regenerative medicine.
Regenerative MedicineNeurologyOrthopedicsDermatologyReproductive HealthOphthalmology
Technology Platform
GMP‑compliant isolation, expansion, and characterization of adult MSCs from bone marrow, adipose, and extra‑embryonic sources, plus a minimal‑manipulation exosome purification workflow.
Opportunities
Regulatory approval of its MSC and exosome products could unlock large domestic and export markets; partnerships with global pharma could accelerate technology transfer and commercialization.
Risk Factors
Reliance on limited clinical data, stringent regulatory pathways for cell therapies, and intense competition from established Indian and multinational stem‑cell companies.
Competitive Landscape
Competes with Indian firms like Stempeutics and Theracell; differentiation is based on multi‑source cell platforms and exosome offerings, but must prove clinical efficacy to stand out.